There is simply no other way to describe the rise of Novavax (NVAX) as anything other than phenomenal. Shares of the vaccine specialist are up by 1,844% year-to-date and we are not even at the halfway point. As the last week has made clear, COVID-19 is not about to disappear anytime soon. With Novavax firmly in the mix among those hoping to bring a solution to market, can the biotech replicate 1H20’s performance in the latter half of the year?That’s a big ask, although B Riley FBR analyst Mayank Mamtani expects Novavax to keep up the momentum.Pointing out several catalysts …read more
Source:: Yahoo Finance
